APT Pharmaceuticals Closes $9M Series A

Tucson, Arizona-based APT Pharmaceuticals said this morning that it has closed a $9M, Serires A funding round. The firm received the funding from Charter Life Sciences and Research Corporate Technologies, with participation by Vivo Ventures. APT is developing biopharmaceuticals for the treatment of asthma, chronic pulmonary obstructive disease, rhinitis and rhinovirus infection. The company said that it will use the additional capital to accelerate its pulmonary and nasal clinical development program. More information »